Importantly, recent findings show that patients with NSCLC areknown to have mutations in both ATM and TP53 genes and are characterized by elevated tumor mutation burden and superior response to immune checkpoint inhibitors, suggesting that this co-mutation may have implications as a biomarker for guiding immune checkpoint inhibitors treatment [37]. Here, ATM is linked to non-small cell lung carcinoma.